20 completed, 11 recruiting, 7 active not recruiting, 3 terminated. 22 Phase 2, 15 Phase 1, 2 Phase 3, 1 Early Phase 1, 1 Not applicable.
Follow Recurrent Endometrial Carcinoma: new trials by email Literature Review of Recurrent Endometrial Carcinoma trials Research Report on Recurrent Endometrial Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Elacestrant With Everolimus for the Treatment of Recurrent Advanced or Metastatic ER-Positive Endometrial Cancer Biospecimen Collection, Computed Tomography, Elacestrant - Advanced Endometrial Carcinoma, Metastatic Endometrial Carcinoma | Phase 2 | Not yet recruiting | Jonsson Comprehensive Cancer Center | 50 | 2026-12-18 | 2026-06-09 |
| Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer Bevacizumab, Biospecimen Collection, Carboplatin - Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma | Phase 3 | Recruiting | National Cancer Institute (NCI) | 255 | 2026-01-27 | 2026-10-22 |
| Avelumab and M1774 in ARID1A-mutated Endometrial Cancer Avelumab, M1774 - Endometrial Cancer, ARID1A Gene Mutation | Phase 2 | Recruiting | Panagiotis Konstantinopoulos, MD, PhD | 25 | 2024-11-14 | 2026-01-07 |
| First-line Carboplatin and Paclitaxel in Combination With Pembrolizumab, Followed by Maintenance Pembrolizumab With or Without Nesuparib, in Patients With Newly Diagnosed Advanced or Recurrent MMR-proficient (pMMR) Endometrial Cancer Nesuparib, Pembrolizumab - Endometrial Cancer, Recurrent Endometrial Carcinoma | Phase 2 | Recruiting | Yonsei University | 92 | 2024-09-12 | 2025-04-03 |
| Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform Biospecimen Collection, Tissue Collection - Early Stage Triple-Negative Breast Carcinoma, Metastatic Bladder Urothelial Carcinoma | Recruiting | Mayo Clinic | 324 | 2024-04-24 | 2026-03-12 | |
| Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer nab-sirolimus - Endometrial Cancer, Endometrioid Tumor | Phase 2 | Recruiting | Aadi Bioscience, Inc. | 29 | 2023-12-28 | 2025-11-13 |
| Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection - Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 65 | 2023-12-18 | 2026-10-21 |
| Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers Biopsy Procedure, Biospecimen Collection, Cobimetinib - Advanced Endometrial Carcinoma, Metastatic Endometrial Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 42 | 2023-09-14 | 2026-10-09 |
| Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy - Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 165 | 2023-04-25 | 2026-10-13 |
| Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma Lenvatinib, Pembrolizumab, Hypofractionated External Beam Radiation Therapy - Recurrent Endometrial Carcinoma, Unresectable Endometrial Carcinoma | Phase 1 | Recruiting | Aaron Wolfson | 18 | 2023-04-15 | 2026-08-03 |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial Alpelisib, Binimetinib, Biopsy Procedure - Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8 | Phase 2 | Recruiting | National Cancer Institute (NCI) | 2900 | 2023-04-07 | 2026-10-15 |
| Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation Bevacizumab, Niraparib - Recurrent Endometrial Carcinoma, Recurrent Ovarian Carcinoma | Phase 2 | Terminated | University of Oklahoma | 9 | 2023-02-15 | 2026-06-03 |
| Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma Biospecimen Collection, Computed Tomography, Ipilimumab - Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 81 | 2022-06-02 | 2026-10-21 |
| Endometrial Cancer Recurrence in Patients Taking Metformin Metformin use - Recurrent Endometrial Carcinoma | Withdrawn | WellSpan Health | 2021-12-27 | 2025-03-28 | ||
| Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Lenvatinib, Paclitaxel, Pembrolizumab - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 2 | Active not recruiting | Floor Backes, MD | 38 | 2021-09-01 | 2026-10-21 |
| Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer Biopsy, Carboplatin, Paclitaxel - Lynch Syndrome, Recurrent Endometrial Carcinoma | Early Phase 1 | Terminated | Floor Backes, MD | 2 | 2021-07-01 | 2025-02-13 |
| Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer Abemaciclib, Anastrozole, Letrozole - Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma | Phase 2 | Recruiting | Jonsson Comprehensive Cancer Center | 32 | 2020-10-16 | 2026-07-17 |
| Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers Entinostat, Olaparib - Fallopian Tube Cancer, Fallopian Tube Carcinosarcoma | Phase 1 | Terminated | Vanderbilt-Ingram Cancer Center | 3 | 2020-10-01 | 2022-04-04 |
| Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers Quality-of-Life Assessment, Radiation Therapy, Talazoparib - Malignant Female Reproductive System Neoplasm, Recurrent Cervical Carcinoma | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 24 | 2019-09-26 | 2026-03-11 |
| Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer Carboplatin, Computed Tomography, Paclitaxel - Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 813 | 2019-08-22 | 2026-10-21 |
Showing 20 of 44. Sign in to see all of them.
Endometrial Neoplasms (44) · Fallopian Tube Neoplasms (13) · Ovarian Neoplasms (10) · Uterine Cervical Neoplasms (9) · Carcinoma, Ovarian Epithelial (8) · Breast Neoplasms (5) · Carcinoma, Non-Small-Cell Lung (5) · Vaginal Neoplasms (5) · Carcinoma, Renal Cell (4) · Carcinosarcoma (4) · Vulvar Neoplasms (4) · Breast Neoplasms, Male (3) · Carcinoma, Hepatocellular (3) · Esophageal Neoplasms (3) · Prostatic Neoplasms (3)
Female Urogenital Diseases (44) · Female Urogenital Diseases and Pregnancy Complications (44) · Genital Diseases (44) · Genital Diseases, Female (44) · Genital Neoplasms, Female (44) · Neoplasms by Site (44) · Urogenital Diseases (44) · Urogenital Neoplasms (44) · Uterine Diseases (44) · Uterine Neoplasms (44) · Neoplasms (43) · Adnexal Diseases (20) · Endocrine System Diseases (19) · Gonadal Disorders (19) · Ovarian Diseases (19)
Specimen Handling (10) · Magnetic Resonance Spectroscopy (8) · Biopsy (7) · Paclitaxel (7) · Taxes (7) · Carboplatin (5) · Sirolimus (5) · pembrolizumab (5) · temsirolimus (5) · Bevacizumab (4) · Nivolumab (3) · olaparib (3) · CTLA-4 Antigen (2) · Everolimus (2) · Interleukin-12 (2)
National Cancer Institute (NCI) (20) · M.D. Anderson Cancer Center (5) · Case Comprehensive Cancer Center (2) · Floor Backes, MD (2) · Jonsson Comprehensive Cancer Center (2) · Mayo Clinic (2) · University of Southern California (2) · Aadi Bioscience, Inc. (1) · Aaron Wolfson (1) · Endocyte (1) · Ohio State University Comprehensive Cancer Center (1) · Panagiotis Konstantinopoulos, MD, PhD (1) · University of Oklahoma (1) · Vanderbilt-Ingram Cancer Center (1) · WellSpan Health (1)
United States (38) · Canada (5) · Puerto Rico (3) · South Korea (2) · Japan (1)
Amit Oza (3) · Floor Backes, MD (2) · Shannon N Westin (2) · William Carson (2) · Aaron H Wolfson, MD, FACR (1) · Agustin Garcia (1) · Amanda N Fader (1) · Amir A Jazaeri (1) · Barbara Andersen, PhD (1) · Carol Aghajanian (1) · D. Scott McMeekin (1) · Dev Mukhopadhyay, PhD (1) · Don Dizon (1) · Eav Lim, DO (1) · Edwin Alvarez (1)
PMID 22922531, PMID 32379297, PMID 35288469, PMID 36972022, PMID 37185961, PMID 37411031, PMID 38431043, PMID 38471508, PMID 40044930, PMID 40685312, PMID 40791544, PMID 41484629, PMID 41514313, PMID 41528970, PMID 42823426
U10CA027469 (6), U10CA180868 (5), U01CA076576 (2), P30CA014089 (1), P30CA016672 (1), P30CA044579 (1), R01CA207240 (1), R21CA135005 (1), U01CA132123 (1), U10CA180820 (1), UM1CA186644 (1), UM1CA186709 (1)